P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

FROM THE NEWS, WE SELECT

NDReg3

Date: 01 Apr 2008
Time: 15:45:54

Comments

http://www.extremeasses.com/main.htm?id=chikenn http://www.primecups.com/go/485861/21/9/n/ http://www.herfirstdp.com/?revid=28792 http://www.hisfirsthugecock.com/?revid=28792 http://www.milfhunter.com/main.htm?id=chikenn http://megapornmall.com/re_milfreg_A http://www.tamedteens.com/go/485861/22/9/n/ http://www.squirthunter.com/?revid=28792

Date: 10 Jul 2001
Time: 12:02:07

Comments

MILLENNIUM

It is not unusual that Millennium Pharmaceuticals, Inc. (MLNM) licenses the BioRS(TM) Integration and Retrieval Plus System (version 4.0).from Biomax. Millennium has its eyes open on every facilitating technology that fits its plans and programs. MLNM will use BioRS(TM as a bioinformatics tool in its impeccable technology platform.

This is how MLNM acts. It continuously evaluate software and technology products, and services that will help enhance its productivity. Millennium made its decision after an extensive analysis of the BioRS system over several months. The system proved to be “stable, comprehensive and efficient”. It fit Millennium requirements, which are speed and agility to assess drug targets in its gene-to-patient platform.

Millennium needed a system that “can handle a broad spectrum of user scenarios for large data volumes”. It got it. The BioRS system did meet Millennium requirements.

THE SYSTEM

As described, the BioRS Plus system offers the ability to integrate and work with relational databases. This user-friendly design is recognized as a very attractive feature for administrators. It also facilitates an efficient development of configurations for various research groups without the need to devote unnecessary time to learn how to operate the system. The BioRS system, first launched in 1998, is a high-speed, sophisticated search and retrieval system for biological information, such as DNA sequences. The speed and flexibility of the BioRS system greatly facilitates gene discovery projects, including genomics, proteomics and drug targeting and delivery.

The system enables researchers to quickly and efficiently retrieve all known biological data on a given topic, independent of the size of the database or the complexity of the query. The BioRS system uses convenient web interfaces and standardizes data formats from different databases using Extensible Markup Language (XML) for quick, easy access to data, independent of the source format. Both flat-file and relational databases, including proprietary databases, are easily integrated.

In January 2001, Biomax granted InforMax of Rockville, Maryland, exclusive, worldwide distribution rights to the BioRS Integration and Retrieval System.

BIOMAX

Biomax Informatics AG (Martinsried, Germany), a leader in the development of customized bioinformatics solutions, developed the well-known Pedant-Pro(TM) Sequence Analysis Suite, the HarvESTer EST Assembly and Clustering System, and other bioinformatics tools used in metabolic pathway, proteomics, and gene expression analyses. Additional information about Biomax can be found at the company's site on the World Wide Web at www.biomax.de.

MILLENNIUM

Millennium Pharmaceuticals is a leading biopharmaceutical company. It applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of delivering personalized medicine. Through the industrialization of this gene-to-patient platform, Millennium is also striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, MA., Millennium currently employs more than 1,400 people.

GENZYME TRANSGENICS

Genzyme Transgenics (GZTC) will release the financial results of its second quarter 2001 on Thursday, July 19, 2001, before the Nasdaq market opens.

A conference call will be webcast with financial analysts live on the Company's internet site at 10:00 a.m. Eastern Time on July 19.

The Company anticipates reviewing its financial progress and expectations. James A. Geraghty, Chairman of the Board, will lead the call. To access the live call or the archive, log onto http://www.transgenics.com. Please connect to the Company's website prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

Genzyme Transgenics Corporation is a leader in developing medicines from the milk of specially bred animals, primarily goats.

Many of the medicines under development are monoclonal antibodies and immunoglobulin fusion proteins.

To date, GTC has formed more than a dozen collaboration agreements which provide for production of specific proteins. Additional information is available on GTC's web site, http://www.transgenics.com.

LION BIOSCIENCE

LION bioscience AG Launches New Software For Genome Research: SRS everEST™ SRS everEST™: software for clustering of Expressed Sequence Tags (ESTs) and powerful extension to LION's suite of solutions for genome research

A Press Release

HEIDELBERG, Germany, July 10, 2001 LION bioscience AG (Neuer Markt: LIO, WKN 504 350, Nasdaq: LEON) today announced the release of SRS everEST™ 1.0, its new complete transcript reconstruction software, essential for the discovery and analysis of genes. The new module will complement LION's Life Science Informatics platform as the basis for its i-Biology® solution, which is being developed to reengineer and shorten the life science industry's product development cycle. LION has already sold SRS everEST™ to customers including Nestlé SA and Intervet Innovation GmbH.

"The majority of EST clustering tools do not go beyond the assembly stage. However, obtaining biological information about the EST consensus sequences and reconstructed genes is of utmost importance," said Dr. Paul Selzer, Head of Bioinformatics at Intervet Innovation GmbH. "With SRS everEST™ we can achieve this goal more quickly, because we can rely on the singular power of SRS in assigning functions to genes, as well as the robustness of state of-the-art clustering software. Within SRS everEST™, we now have a wealth of information from our own databases as well as from the public domain directly at hand."

SRS everEST™ enables efficient clustering of Expressed Sequence Tags (ESTs) as well as the assignment of biological information to the clusters. EST projects for more than 250 organisms are currently ongoing globally, with the number of projects expected to increase in the future. Through its direct link to LION's SRS data integration system, SRS everEST™ allows the unique assignment of biological information to gene sequences, while its advanced graphical representations enable intuitive and straight forward data analysis.

SRS everEST™ uses the latest EST clustering functionality provided by stackPACK™, which was developed by Electric Genetics (Capetown, South Africa). stackPACK™ is the only peer-reviewed clustering system available, and quickly constructs full- or extended-length gene sequences from fragmented data. Due to the specialized technology of stackPACK™, alternate expression or transcript variants can be identified, which may remain undetected with other EST clustering tools.

"SRS everEST™ is the first software on the market to facilitate quick assembly of ESTs and the connection of the resulting clusters with the wealth of biological data available in the public domain," said Dr. Jan Mous, Chief Scientific Officer at LION bioscience. "SRS everESTä is an important new module in our suite of products for cutting-edge genomics research. It allows researchers to keep up with the increasing fast-paced developments in the field of genomics and transcriptomics.

For further information please refer to http://www.lionbioscience.com/srseverest

PROHOST COMMENTS

Millennium does the best. Selects the best and does not spare money or effort to become a full-fledged superior pharmaceutical company of the future.

Genzyme Transgenics, we believe, will contribute a great deal into solving the bottleneck problem of biological drug production

Lion Bioscience is proving its capability to upgrade its technologies and systems on continuous basis. The firm's technology will never be outdated. Lion is always on the top of the world with regard to its science and technologies.

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName